TransMedics Group (FRA:8T8) Debt-to-Revenue : 1.19 (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is TransMedics Group Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

TransMedics Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €2.3 Mil. TransMedics Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €464.6 Mil. TransMedics Group's annualized Revenue for the quarter that ended in Sep. 2024 was €392.0 Mil. TransMedics Group's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 1.19.

TransMedics Group Debt-to-Revenue Historical Data

The historical data trend for TransMedics Group's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TransMedics Group Debt-to-Revenue Chart

TransMedics Group Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

1.45

1.35

1.45

0.72

2.14

TransMedics Group Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Revenue	Get a 7-Day Free Trial															1.94	1.59	1.33	1.13	1.19

Competitive Comparison of TransMedics Group's Debt-to-Revenue

For the Medical Devices subindustry, TransMedics Group's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TransMedics Group's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, TransMedics Group's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where TransMedics Group's Debt-to-Revenue falls into.

TransMedics Group Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

TransMedics Group's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.866	+	471.256)	/	221.568
	=	2.14

TransMedics Group's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(2.291	+	464.558)	/	391.976
	=	1.19

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.

TransMedics Group Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of TransMedics Group's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

TransMedics Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TransMedics Group Inc (FRA:8T8) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

TMDX:USA

Address

200 Minuteman Road, Andover, MA, USA, 01810

Website

https://www.transmedics.com

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

TransMedics Group Headlines

No Headlines